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doi:10.1Objective: The treatment of patients with ischemic cardiomyopathy and concomitant mitral regurgitation can
be challenging and is associated with reduced long-term survival. It is unclear how mitral valve repair versus
replacement affects subsequent outcome. Therefore, we conducted this study to understand the predictors of
mortality and to delineate the role of mitral valve repair versus replacement in this high-risk population.
Methods: From 1993 to 2007, 431 patients (mean age, 70  9 years) with ischemic cardiomyopathy (left
ventricular ejection fraction  45%) and significant ischemic mitral regurgitation (>2) were identified.
Patients (44) with concomitant mitral stenosis were excluded from the analysis. A homogeneous group of
387 patients underwent combined coronary artery bypass grafting and mitral valve surgery, mitral valve re-
pair in 302 (78%) and mitral valve replacement in 85 (22%). Uni- and multivariate analyses were performed
on the entire cohort, and the predictors of mortality were identified in 2 distinct risk phases. Furthermore, we
specifically examined the impact of mitral valve repair versus replacement by comparing 2 propensity-
matched subgroups.
Results: Follow-up was 100% complete (median, 3.6 years; range, 0–15 years). Overall 1-, 5-, and 10-year sur-
vivals were 82.7%, 55.2%, and 24.3%, respectively, for the entire group. The risk factors for an increased mor-
tality within the first year of surgery included previous coronary artery bypass grafting (hazard ratio ¼ 3.39;
P<.001), emergency/urgent status (hazard ratio ¼ 2.08; P ¼ .007), age (hazard ratio ¼ 1.5; P ¼ .03), and
low left ventricular ejection fraction (hazard ratio ¼ 1.31; P ¼ .026). Thereafter, only age (hazard
ratio ¼ 1.58; P<.001), diabetes (hazard ratio ¼ 2.5; P ¼ .001), and preoperative renal insufficiency (hazard
ratio ¼ 1.72; P ¼ .025) were predictive. The status of mitral valve repair versus replacement did not influence
survival, and this was confirmed by comparable survival in propensity-matched analyses.
Conclusions: Survival after combined coronary artery bypass grafting and mitral valve surgery in patients with
ischemic cardiomyopathy (left ventricular ejection fraction  45%) and mitral regurgitation is compromised
and mostly influenced by factors related to the patient’s condition at the time of surgery. The specifics of mitral
valve repair versus replacement did not seem to affect survival. (J Thorac Cardiovasc Surg 2011;142:995-1001)Earn CME credits at
http://cme.ctsnetjournals.org
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The Journal of Thoracic and Cachallenging groups to treat in cardiac surgery. Some of these
patients have 2 independent disease processes of coronary
ischemia and myxomatous MR, and they tend to have
a favorable survival outcome after surgical correction.1-3
However, the outcome seems to be more guarded in those
who have coronary ischemia and functional MR, that is,
ischemic MR (IMR).4 In this population, IMR can be due
to various pathophysiologic processes ranging from acute
papillary muscle ischemia/rupture to chronic left ventricu-
lar (LV) remodeling after myocardial infarction, resulting
in tethered and incompetent mitral leaflets unable to coapt.
Accordingly, their clinical presentation varies, ranging from
acute pulmonary edema to recurrent bouts of congestive
heart failure. This has been shown to influence the surgeon’s
decision to perform mitral valve repair (MVP) or mitral
valve replacement (MVR).5,6 All these factors contribute
to the difficulty in understanding the comparative efficacy
of MVP versus MVR, and it is not surprising to haverdiovascular Surgery c Volume 142, Number 5 995
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
HR ¼ hazard ratio
ICM ¼ ischemic cardiomyopathy
IMR ¼ ischemic mitral regurgitation
LAD ¼ left anterior descending
LITA ¼ left internal thoracic artery
LV ¼ left ventricular, left ventricle
LVEF ¼ left ventricular ejection fraction
MR ¼ mitral regurgitation
MV ¼ mitral valve
MVP ¼ mitral valve repair
MVR ¼ mitral valve replacement
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Dconflicting literature reports supporting MVP or MVR.7
Furthermore, many of the reported experiences have short-
comings of small sample size, experiences accumulated
over many decades of evolving practices, and a heteroge-
neous patient population.8 Nonetheless, the current general
consensus seems to favor MVP over MVR in patients with
IMR even though a significant rate of MR recurrence is
a well-recognized fact.9,10 The rate of MR recurrence
after MVP seems to be particularly high in patients with
poor left ventricular ejection fraction (LVEF), and this
may adversely affect survival. We conducted this study
specifically to examine these perplexing issues in
a currently relevant cohort of patients with significant
ischemic cardiomyopathy (ICM) and IMR. The primary
objective was to understand the risk factors associated
poor survival after combined coronary artery bypass
grafting (CABG) and MVP/MVR in patients with an
LVEF 45% or less. The secondary objective was to
understand the impact of MVP versus MVR on survival.PATIENTS AND METHODS
Study Design
This is a retrospective analysis of prospectively gathered data over more
than a 10-year period (median, 3.6 years; range, 0–15 years). The cardiac sur-
gery database (1993–2007) at Mayo Clinic (Rochester, Minn) was used to
create a homogeneous study cohort of patients who underwent cardiac sur-
gery for ischemic heart disease with significant IMR. We identified patients
who underwent a combined CABG and MVP or MVR first. Then, we ex-
cluded thosewho have had any one of the following conditions: LVEFgreater
than 45%, infective endocarditis, congenital valvular heart disease, rheu-
matic valvular disease, or any degree of mitral stenosis. All patients with
mixed pathologies were thoroughly assessed, as echocardiographic data
and operative findings were reviewed to confirm the ischemic cause of the
MR. The Mayo Foundation Institutional Review Board approved this study,
and individual consent was obtained for all patients included in this study.
We explored themortality hazards for the entire cohort in 2 different risk
phases (early up to 1 year after surgery and late thereafter). Statistically sig-
nificant risk factors for mortality were identified for each of these 2 risk
phases. Furthermore, we examined the specific impact related to the type
of mitral valve (MV) procedure by comparing 2 subgroups based on996 The Journal of Thoracic and Cardiovascular SurgMVP andMVR, propensitymatched on 14 baseline characteristic variables
(age, gender, hypertension, diabetes, history of smoking, body surface area,
preoperative New York Heart Association class, chronic renal failure, pre-
operative dialysis, previous CABG surgery, previous valve procedure, his-
tory of congestive heart failure, LVEF, and emergency/urgent status of the
procedure).
Definitions
The cause of MR was presumed to be ischemic. All patients had a sig-
nificant degree of mitral annular dilation and LV dysfunction due to prior
myocardial infarction. In patients who required more complex repair for
mixed valvular pathology, operative and echocardiography reports were re-
viewed to confirm that myocardial ischemia was the primary mechanism
for MR. The operative and echocardiographic findings were reviewed in
detail in these patients, and they were deemed to have IMR on the basis
of leaflet tethering, prior myocardial infarction, and leaflet tethering. All
patients included in this study had an undersized ring/band implanted
when applicable. In patients with repairs, the ring was chosen according
to the undersized intercommissural distance when applicable. In patients
with a 63- to 65-mm posterior band, the band was cut and undersized to
the appropriate length. The exact nature of chordal preservation in each
patient undergoing MVR was not established. However, our institutional
policy has been to preserve the posterior leaflet whenever possible with
an increasing recent tendency toward preserving as much of the anterior
leaflet and by transposing it to the posterior annulus.
Follow-up
Patients were followed systematically by using mailed questionnaires,
telephone interview, or examination at the Mayo Clinic. Clinical follow-
up for both patients with MVR and MVP was 100% complete. Mean
follow-up among survivors was 4.2 years (range, 0–15.7 years).
Statistical Analysis
Descriptive statistics for categoric variables are reported as frequency
and percentage, and continuous variables are reported as mean (standard
deviation) or median (range) as appropriate. Categoric variables were
compared between MVP and MVR groups using the chi-square test, and
continuous variables were compared using 2-sample t test or Wilcoxon
rank-sum test when appropriate. The Kaplan–Meier method was used to
draw survival curves and calculate 1-, 5-, and 10-year survival statistics.
Cox regression models were used to find the univariate and multivariate
predictors of early (1-year) and long-term (late or constant) survivals.
The multivariable model considered univariate significant variables
(P<.05) with model selection using the stepwise method (backward and
forward methods resulted in the same model). All statistical tests were
2-sided with the alpha level set at .05 for statistical significance.RESULTS
Patient Characteristics
From 1993 to 2007, 431 patients were identified and re-
quired a combined CABG and MVP/MVR procedure. Of
these, 44 patients were excluded because they had mitral
stenosis, yielding 387 patients for this study. The mean
age at the time of surgery was 70.1  9.1 years (range
43–91 years), and 261 patients were male (67%). CABG
surgery was performed in all patients. MVP was performed
in 302 patients (78%), and MVR was performed in 85 pa-
tients (22%). All patients had LV dysfunction (LVEF 
45%), and the mean LVEF by preoperative transthoracic
echocardiography was 33.6%  8.4% (range, 9–45).ery c November 2011
TABLE 1. Patient characteristics
Risk factors All groups, n ¼ 387 Repair, n ¼ 302 Replacement, n ¼ 85 P value
Age (y) 70.1  9.1 70.3  8.8 69.5  9.9 .93
Female (n,%) 126 (33,1) 95 (31.5) 31 (36.5) .38
Hypertension (n,%) 273 (70.5) 215 (71.2) 58 (68.2) .59
Diabetes (n,%) 126 (32.5) 104 (34.4) 22 (25.9) .14
History of smoking (n,%) 252 (65.1) 200 (66.2) 52 (62.2 .22
BSA (m2) 1.9  0.2 1.9  0.2 1.9  0.2 .31
NYHA class III or IV (n,%) 335 (86.6) 257 (85.2) 78 (91.3) .11
Chronic renal failure (n,%) 39 (10.1) 31 (10.3) 8 (9.4) .82
Preoperative creatinine (mg/dL) 1.6  0.9 1.6  1.1 1.5  0.7 .68
Preoperative dialysis (n,%) 7 (1.8) 5 (1.6) 2 (2.4) .67
Previous CABG surgery (n,%) 51 (13.2) 28 (9.3) 23 (27.1) <.0001
Previous mitral procedure (n,%) 23 (5.9) 8 (2.6) 15 (17.6) <.0001
History of CHF (n,%) 226 (58.4) 178 (58.9) 48 (56.5) .68
LVEF (%) 33.6  8.4 33.6  8.5 34.3  7.9 .50
Emergency/urgent operation (n,%) 13 (3.4) 10 (3.3) 3 (3.5) .96
BSA, Body surface area; CHF, congestive heart failure; NYHA, New York Heart Association.
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cording to the MV procedure (repair vs replacement) are
presented in Table 1. The patients in the MVR group had
a significantly higher incidence of CABG (27.1% vs
9.3%; P < .0001) or MV surgery (17.6% vs 2.6%;
P<.0001) in the past.
Operative Details
Table 2 summarizes the operative details for all patients
included in this study. All surgeries were performed
through a median sternotomy using cardiopulmonary by-
pass, blood cardioplegia, and the standard aortic cross-
clamping operative technique. The LITA was used inTABLE 2. Operative details
Procedure details All groups, n ¼ 387
Mitral repair (n ¼ 302 patient)
Annuloplasty (n,%) 302 (100)
Concomitant leaflet resection (n,%) 31 (8)
Ring/band sizes (mm)
24–28 128 (42)
30–34 109 (36)
63–65 69 (22)
Mitral replacement (n ¼ 85 patients)
Bioprosthesis (n,%) 46 (12)
Mechanical (n,%) 39 (10)
LITA use (n,%) 290 (75)
No. of distal anatomosis (n,%)
1 109 (28)
2–4 262 (68)
>4 16 (4)
Concomitant valve procedures
Aortic valve replacement 60 (15)
Tricuspid valve repair/replacement 41 (11)
Cardiopulmonary bypass time (min) 124.4  47.5
Aortic crossclamping time (min) 82.2  31.6
The Journal of Thoracic and Ca290 patients (75%). MVP comprised implanting a poste-
rior annuloplasty ring/band only in 279 patients (92%).
Thirty-one patients (8%) required a more complex repair
for mixed valvular lesions. In patients undergoing MVR,
46 (54%) received a bioprosthetic valve and 39 (46%) re-
ceived a mechanical valve. The mean cardiopulmonary
bypass time was 124.4  47.5 minutes (range, 30–340),
and the mean aortic crossclamp time was 82.2  31.6 min-
utes (range, 16.5–46.4). The number of treated patients per
year was consistent throughout the study period, and the
survival was not affected by the surgical era (data not
shown; P ¼ .69).Overall Survival Analysis
The observed in-hospital or 30-day mortality was 5% (21
patients). The overall reported 1-, 5-, and 10-year survivals
for the entire cohort were 84.0%, 55.4%, and 25.4%, re-
spectively (Figure 1). The Kaplan–Meier survival curve
had 2 different mortality risk phases: an acute phaseFIGURE1. Overall reported 1-, 5-, and 10-year survivals for the entire co-
hort were 82.7%, 55.2%, and 24.3%, respectively.
rdiovascular Surgery c Volume 142, Number 5 997
TABLE 3. Multivariate risk factor analysis for death in patients
undergoing concomitant coronary artery bypass grafting and mitral
valve surgery
Early (1-y)
hazard
Late
(constant hazard)
Risk factors HR (P value) HR (P value)
Previous CABG surgery 3.39 (<.001)
Emergency/urgent status 2.08 (.007)
LVEF (per 10% decrease) 1.31 (.02)
Age 1.50 (.026) 1.58 (<.001)
Renal insufficiency 1.72 (.025)
Diabetes 2.50 (<.001)
Multivariate Cox regression analysis model for early (1-year) and late (constant)
survivals.
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(constant) phase.
Predictors of Early (1-Year) and Late (Constant)
Mortality
Table 3 summarizes identified risk factors based on mul-
tivariate Cox’s regression analyses. Previous CABG surgery
(hazard ratio [HR]¼ 3.39; P<.001), emergency/urgent sta-
tus of the procedure (HR¼ 2.08; P¼ .007), age (HR¼ 1.5;
P¼ .03), and low LVEF (HR¼ 1.31;P¼ .026) were predic-
tive of earlymortality. The factors found to influence the late
(constant) mortality were age (HR¼ 1.58; P<.001), diabe-
tes (HR ¼ 2.5; P ¼ .001), and preoperative renal insuffi-
ciency (HR ¼ 1.72; P ¼ .025). The type of MV procedure
performed (MVP or MVR) did not influence early or late
mortality.
Propensity-Matched Comparisons Comparing
Mitral Valve Procedures
We noted comparable survival between 2 propensity-
matched subgroups composed of 76 patients in each type
of MV procedure. There were no significant differences be-
tween the MVP and MVR groups; 1-year (81.9% vs
79.6%; P ¼ .72) and 5-year (44.0% vs 54.2%; P ¼ .72)
survivals were comparable.
DISCUSSION
The resurgence of interest in MVP over the past decade
has provided long-term data supporting the superiority of
repair over replacement in patients with normal LV function
or degenerative/myxomatous valve disease.11 With valve-
related advantages aside, it is generally accepted that in
this population, MVP has demonstrated improvements
over MVR in terms of heart function recovery and long-
term survival.12 However, in patients with ICM and IMR,
the impact of MVP over MVR remains controversial. Few
retrospective studies have focused on the predictors of sur-
vival in patients with severe IMR and ICM.7,8,13 The present
study included patients who underwent a combined CABG998 The Journal of Thoracic and Cardiovascular Surgand MVP/MVR for significant ICM (LVEF  45%) and
significant IMR over the past 15 years.
Key Findings
The survival curve of our entire cohort demonstrated 2
different mortality risk phases as shown in Figure 1. Ac-
cordingly, we divided the mortality risk analyses into the
early phase (up to 1 year after surgery) and the late phase
(beyond the first year). This is concordant with previously
published studies by Gillinov and associates7 describing
distinct phases of instantaneous risk of death in these pa-
tients. In our study, factors influencing mortality in the early
phase included a history of CABG surgery (HR ¼ 3.39;
P < .001), emergency/urgent status of the surgery
(HR ¼ 2.08; P ¼ .007), age (HR ¼ 1.5; P ¼ .03), and
low LVEF (HR ¼ 1.31; P ¼ .026), as shown in Table 3.
These risk factors were reflective of the associated technical
challenges of a redo CABG surgery, patient’s medical status
requiring nonelective surgery, and poor cardiac reserve. The
finding of these risk factors is consistent with our clinical
impression that an expected mortality within the first year
would be high, for example, in a patient with an LVEF of
30% who would require a technically challenging redo
CABG and MVP/MVR on an emergency/urgent basis.4
For this patient, the expected operative mortality (30-day
or in-hospital) also would be high, but we were unable to
performmeaningful multivariate analyses for this end point,
because the operative mortality observed in this study was
low (5%).
Once patients survived the first year, their subsequent
mortality was mostly based on their noncardiac comorbid-
ities of diabetes (HR ¼ 2.5; P ¼ .001), renal insufficiency
(HR ¼ 1.72; P ¼ .025), and age (HR ¼ 1.58; P< .001).
One could speculate many potential reasons for the finding
that none of the cardiac specific risk factors played a role on
survival during the late phase. One of the major reasons may
be that because all patients in the study started with poor
cardiac reserve (LVEF  45% with significant MR) before
surgery, such significant underlying cardiac dysfunction
had a uniform and overwhelming influence on survival.
The specifics of mitral surgery (MVP vs MVR) had no
influence on survival in the early or late risk phase in this
study cohort. Furthermore, in small subgroup analysis, we
confirmed that the type of repair (rigid/flexible, complete/
partial, concomitant leaflet procedure) did not influence
survival in patients with repairs (P ¼ .24).
We examined the issue of MVP versus MVR in this spe-
cific population by comparing 2 propensity subgroups. We
identified a matching pair of patients undergoing MVP for
76 of 85 patients undergoingMVR on the basis of 14 impor-
tant clinical variables, as mentioned in the ‘‘Materials and
Methods’’ section. As shown in Figure 2, survival in these
patients with an LVEF 45% or less was comparable be-
tween patients with MVR and MVP. This is comparableery c November 2011
FIGURE 2. Survival results for propensity-matched patients. There were
no differences between patients undergoing MVR or MVP. Survival was
comparable between propensity-matched groups of patients (P ¼ .72).
MV, Mitral valve.
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limited after MV operation and CABG, with no advantage
of either strategy for managing the MV.4,7,14 Gillinov and
associates7 also attempted to address the question of MVP
versus MVR. Their surgical practice of MVP versus MVR
was significantly confounded with the patient’s condition,
and their matched pair yielded ‘‘only one end of spectrum
of IMR (the most complex with the sickest patients).’’
They exercised sophisticated and elaborate statistical anal-
yses to compare different quintile risk subgroups based on
propensity-adjusted for MVP versus MVR selection
factors. The experience reported by Grossi and associates8
further demonstrated a high degree of confounding relation-
ship between the type of MV procedure and the preopera-
tive patient characteristics of angina and New York Heart
Association class. In our cohort, we also noted some differ-
ences in baseline characteristics between the MVP and
MVR groups, but such differences were only related to prior
cardiac surgery (Table 1). By selecting a relatively homoge-
neous study population with an LVEF of 45% or less within
the recent surgical era, we were able to compare a meaning-
ful number of propensity-matched patients and examine the
survival impact of MVP versus MVR specifically.
Other Important Considerations
Several groups have shown that survival after coronary
revascularization is strongly influenced by the use of the
left internal thoracic artery (LITA) to the left anterior de-
scending (LAD) artery.15,16 In this study, 75% of patients
with an MV procedure and concomitant CABG had the
LITA to the LAD used. We strongly believe that
previously reported differences in survival observed in
MVP compared with MVR in patients with ICM may be
related to the low incidence of using the LITA to the
LAD, especially in patients with MVR (15%).7 When thereThe Journal of Thoracic and Cais an associated LAD pathology, the LITA should always be
used in this population with ischemic LV function to opti-
mize LV recovery and possibly survival. Furthermore, in
patients with MVP, residual MR can be present and nega-
tively influence the degree of LV recovery and remodeling.
In a recent study performed in 111 patients undergoing
MV surgery, De Bonis and colleagues9 showed that the pro-
gression of LV remodeling paralleled the recurrence of MR.
At 3 years, freedom from recurrence of MR of 2þor greater
was 74% in those who showed a reverse remodeling
process. In a multicenter study, Shiota and associates10
reported a surprisingly high 33% recurrence of MR
6 months after mitral annuloplasty in patients with ICM.
In their study, recurrent MR was associated with increased
LV size and decreased LVEF. Hypothetically, in terms of re-
currence of MR, MVR could represent a more reproducible
and durable surgical treatment in these patients. Of course,
preservation of as much MV apparatus as possible at the
time of MVR would be important.17,18
Limitations
One of the major limitations of our study is that it is a ret-
rospective review of patients who underwent a combined
surgery of CABG and MVP or MVR, in which a selection
bias plays a role, and it is hard to account for all of its impact
on outcome. We also do not have a comparison group with
no concomitant MV procedures. Therefore, the added bene-
fit of MVP/MVR is still speculative on the presumption that
reducing MR renders a therapeutic benefit on outcome. The
proposed National Institutes of Health-sponsored cardiac
surgery network studies of prospective randomized trials
involving patients with IMR would be critically important
in providing further answers in treating these perplexing
and challenging patients. The end points of this study were
predictors of death, and we did not analyze other complica-
tions because we have already described valve procedure-
related differences in durability in the literature.19
CONCLUSIONS
We evaluated the predictors of survival in patients with
ICM and IMR. We identified 2 distinct risk phases based
on the survival curve kinetics. The risk predictors of mortal-
ity during the early phase (1-year) were factors associated
with the patient’s presenting condition and projected techni-
cal difficulty at the time of the intervention (previous
CABG surgery, emergency intervention, low LVEF). In
the late (after the first year) phase, patients’ comorbidities
(age, diabetes, and renal insufficiency) were the determi-
nants of mortality. In patients with ICM and IMR, the nature
of the MV intervention (MVP or MVR) had no influence on
survival.
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Dr Patrick McCarthy (Chicago, Ill). By disclosure, I am
a coinventor of the IMR ETlogix ring (Edwards Lifesciences,
Irvine, Calif).
Congratulations, Dr Maltais, on an excellent and timely presen-
tation. We look forward to the results of the ongoing National1000 The Journal of Thoracic and Cardiovascular SurInstitutes of Health prospective randomized trial that will give fur-
ther information on this important subject.
As you note, patient factors were important to survival, but we
can’t modify those. As surgeons, we can decide, however, between
MVR and MVP. So I have questions about how that decision was
made and late outcomes.
First, can you provide insight into why MVR was sometimes
chosen?Was it influenced by the degree of leaflet tethering or other
factors seen on echocardiography? Was MVR used for worse ven-
tricles or more complex and extensive MR? Others have found no
difference in survival between MVP and MVR in single-center
studies, but did you look at other outcomes, such as need for trans-
plant or ventricular assist device, late New York Heart functional
class, and rehospitalization for cardiac cause, and do you have
any data on late MR recurrence? Finally, after this study, what
do you do now, repair or replace?
DrMaltais.Regarding your first question, this is a retrospective
study with all the biases that it implies. I would say that in our cen-
ter, the most important thing is to achieve a complete repair, and all
the patients are leaving the operating room with trivial MR. That
being said, one could argue that when a patient presents with
a heavy ischemic burden, one will be more inclined to repair the
valve, compared with a patient who presents with an extremely
dilated LV or lots of tethering, where surgeons might be more
inclined to replace the valve. This is, however, certainly a good
question, and it warrants prospective randomized studies to
answer.
In regard to your second question, as you pointed out, lots of
studies have shown that these patients are really sick, especially
the subgroup with low ejection fractions. We don’t have the inci-
dence of ventricular assist device or heart transplantation in this
population because this is a retrospective study. Furthermore, we
don’t have the incidence of late recurrence of MR or readmission
for symptomatic heart failure.
However, in regard to ventricular assist device or heart trans-
plantation, we are certainly looking at this population of sick
patients, and we believe there might be a subgroup of patients
with poor targets for bypasses who could be candidates for
these advanced heart failure therapies even as a first option of
treatment.
In regard to MR recurrence, although all those patients are leav-
ing the operating room with trivial MR, we know the amount of
recurrence of MR is approximately 20% to 30%. This can influ-
ence a surgeon’s decision to replace or repair the valve initially ac-
cording to the patient’s symptoms. If the patient presents with
severe angina symptoms, the most important thing is to perform
CABG, but if the patient presents with long-term congestive heart
failure symptoms, the most important thing is to have no recur-
rence of MR. This might influence the surgeon’s decision.
Dr McCarthy. What would you do now?
Dr Maltais. This is a simple study that has shown us that when
we look at the overall population, the type of procedure didn’t
seem to influence the overall survival. This study was intended
to be simple, to look at what is really important in this population.
From these results, the most important aspect seems to be patient
selection. If the patient has anMVP, it has to be quick and efficient.
Only the underlying patients’ condition and presentation at the
time of surgery seem to influence survival.gery c November 2011
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DDr Ottavio Alfieri (Milan, Italy). May I ask which kind of
repair you carried out?
DrMaltais. This is it. A retrospective study, but more than 90%
of those patients had an undersized ring. Patients with mixed dis-
ease are a little harder to analyze, but all those patients had IMR,
and neochordae and leaflet resection were the most frequent con-
comitant techniques used.
Dr Robert Dion (Genk, Belgium). I would like to return to the
technique. When you repair the valve, do you use a complete,
pliable, or rigid ring? If you undersize, when and how much do
you undersize?
Dr Maltais. With regard to the type of repair, the numbers are
small when we looked at subgroups, but the type of ring did not
change results. Most of the surgeons try to undersize 2 sizes.
Dr Dion. If you replace the valve, do you systematically use
a bioprosthesis, and if you use a bioprosthesis, what sizing are
you applying? Are you aiming at the largest possible size or trying
to somewhat shrink the base of the heart by using some undersiz-
ing? What is the policy?
Dr Maltais. We don’t have any policy to look at those results
specifically. In patients with replacement, all had preservation of
the posterior mitral apparatus, and we believe this is the most
important thing.
Dr Paul Kurlansky (Miami, Fla). Very interesting and provoc-
ativework. As you probably know, there are emerging data on IMR
that although the patients with MR have a worse prognosis, it
doesn’t necessarily seem to matter whether or not you repair/
replace the valve in terms of their long-term survival. So in view
of that, I was just wondering what exactly are your indications
for surgically addressing the MV?
Dr Maltais. Patients with moderate IMR are another topic. But
these are all patients who needed to have a procedure performed on
the MV, and therefore all patients had more than moderate MR. If
repair is possible, this is the procedure of choice.
Dr Thierry Mesana (Ottawa, Ontario, Canada). A great
study, Simon, and great results. We actually presented the
same study with propensity case matching at the Society of
Thoracic Surgeons. First, in your population with MVP, you
had a high number of patients with redos, were these patients
with previous MVR? Second, did you look at the LV function
in both groups? Did you see a difference in recovery of LV func-
tion with one or the other group and eventually LV size changes
after the LV repair versus replacement?
Dr Maltais. In terms of MVR, most of the patients with a pre-
vious MVP had MVR. This was a retrospective study, again, andThe Journal of Thoracic and Carthe hard thing to point out is how many patients had replacement
because they had 1 or 2 failed attempts to repair.
In terms of recurrence of MR and LV remodeling, this is some-
thing we are looking into. Approximately 20% to 30% of those pa-
tients will have recurrence of MR, which reflects the underlying
disease and ventricular problem. In further studies, we will be
looking into LV dimension reduction or recuperation of LV func-
tion as a potential marker of survival in patients with recurrent
MR.
Dr Mesana. A great study, and actually we had presented sim-
ilar results, including the recurrence of MR, which did not affect
long-term survival.
Dr Maltais. Thank you.
Dr Steven Bolling (Ann Arbor, Mich). Simon, a very nice study.
You don’t have long-term echocardiography follow-up on these
patients, is that correct?
Dr Maltais. We do have echocardiography follow-up on those
patients but with midterm follow-up.
Dr Bolling. So then, I will ask you in a different way. Is it pos-
sible that on your curve you actually have 3 groups, good mitral
repair, mitral replacement, and bad mitral repair, meaning a bunch
of patients who had recurrence. Could it be you are not really look-
ing at MVP versus MVR, but whether the patients have recurrent
MR in one group and not in another and whether they were able to
remodel their ventricles. Do you have enough data and follow-up
echocardiography to say that?
Dr Maltais. At this point, I would say we don’t. We are cur-
rently looking at those data and trying to assess this more in detail.
Themain advantage ofMVR compared withMVP is obviously the
fact that all those patients don’t have recurrentMR. As you pointed
out, there might be a subgroup of patients with recurrent MR with
a higher mortality compared with patients with perfect repairs and
MVR.
Dr Soon Park. I think we need to separate a few things out for
discussion. The National Heart, Lung, and Blood Institute Cardio-
thoracic Surgical Trial Network study may inform us about what
might happen to the LV geometry after repair versus replacement,
but it probably will not tell us much about survival. The current
study is a retrospective review, and its primary focus is on survival.
We really do not know how recurrent MR might affect survival or
the impact of MVR, whether it has a significant adverse impact or
not. Clearly, we need to study these issues further in the future.
Meanwhile, this study seems to illustrate important factors that in-
fluence the outcome after surgery in this high-risk group, and it
seems that MVR versus MVP does not make a difference.diovascular Surgery c Volume 142, Number 5 1001
